Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Dec 11, 2008

Premium
Title: Nucleic Acid Delivery
 
Number: 7,462,351
 
Filed: May 25, 2006
 
Lead Inventor: Susan Conroy, Innovata
 
The invention, the patent’s abstract states, “provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eukaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The … invention also provides methods of treatment in combination with such formulations.”
 

 
Title: Method for Determining the Function of Nucleic Acid Sequences and Expression Products Thereby
 
Number: 20080299552
 
Filed: Dec. 22, 2005 PCT Filed: Dec. 22, 2005
 
Lead Inventor: Ugur Sahin, Johannes Gutenberg University
 
“The invention relates to a method for the investigation and determination of the function of nucleic acid sequences and nucleic acid expression products by the introduction of RNA into host cells,” the patent application’s abstract states.
 

 
Title: Nucleic Acid Compounds for Inhibiting ApoB Gene Expression and Uses Thereof
 
Number: 20080299659
 
Filed: Feb. 28, 2008
 
Lead Inventor: Steven Quay, Nastech Pharmaceutical (MDRNA)
 
According to the patent application’s abstract, the invention comprises “meroduplex ribonucleic acid molecules capable of decreasing or silencing ApoB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ApoB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof.”
The patent application also claims “methods of decreasing expression of an ApoB gene in a cell or in a subject to treat an ApoB-related disease,” the abstract states.
 

 
Title: Endogenous Antisense RNA Expression-Analysis System
 
Number: 20080300143
 
Filed: May 30, 2008
 
Inventor: Hidenori Kiyosawa, Riken
 
The patent application, its abstract states, claims “a novel endogenous antisense RNA expression-analysis system capable of comprehensively and highly-precisely detecting endogenous antisense RNA including noncoding antisense RNA.” The invention specifically comprises “a probe set containing one or more probes designed for an antisense strand sequence under the conditions optimal for hybridization, by artificially defining an antisense strand of known cDNA; a microarray containing the AFAS probe set; [and a] detection method of endogenous antisense RNA wherein the microarray and RNA labeling by random priming are combined,” the abstract adds.
 

 
Title: In Vivo High-Throughput Selection of RNAi Probes
 
Number: 20080300145
 
Filed: Oct. 30, 2007
 
Lead Inventor: Vivek Mittal, Cold Spring Harbor Laboratory
 
“In mammalian systems, RNA interference-based suppression of target gene expression may be activated by delivery of RNAi probes such as double-stranded, small interfering RNA molecules or short hairpin RNAs, where the RNAi probe sequence is homologous to the target gene,” the patent application’s abstract states. “A reliable and quantitative method is provided for the rapid and efficient identification of RNAi probes that are most effective in providing RNAi-mediated suppression of target gene expression. This method may be used for high-throughput screens to identify effective RNAi probes.”
 

 
Title: siRNA Targeting Vascular Endothelial Growth Factor Receptor-1
 
Number: 20080300395
 
Filed: July 24, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to VEGFR1.”

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.